Monday, September 21, 2015
Harlan Laboratories, a privately held provider of general and specialty toxicology services through its Contract Research Services (CRS) business, and Fluofarma, a CRO specializing in high content analysis, have partnered to strengthen the companies’ drug discovery and translational medicine services.
Harlan Contract Research Services (CRS), a privately held provider of general and specialty toxicology services, and Bertin Pharma, a global solution provider offering R&D outsourcing services headquartered in France, have announced a strategic partnership for early drug development. The companies will offer a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, especially in the context of regulatory studies.
Germany-based Harlan Contract Research Services (CRS) Cytotest Cell Research has been selected for inclusion in the E.U. Network of Laboratories for the Validation of Alternative Methods (EU-NETVAL). EU-NETVAL provides support for the E.U. Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) to develop methods to reduce, refine or replace animals used for scientific purposes.
CRO Harlan Laboratories, which also provides research models, has expanded its specialty research production facilities in Indianapolis and Livermore, Calif. This expansion more than doubles the number of isolators at these sites, allowing Harlan to meet growing customer demand for its immunocompromised models.